Adjuvant!© Online estimation of chemotherapy effectiveness when added to ovarian function suppression plus tamoxifen for premenopausal women with estrogen-receptor-positive breast cancer

Breast Cancer Research and Treatment

Volumn 123, Issue 1, 2010, Pages 303-310

  Paridaens, Robert J ^a   Gelber, Shari ^b,c   Cole, Bernard F ^b,d   Gelber, Richard D ^b,c,e   Thürlimann, Beat ^f,g   Price, Karen N ^b,c   Holmberg, Stig B ^h   Crivellari, Diana ⁱ   Coates, Alan S ^j   Goldhirsch, Aron ^k,l  

^a UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d University of Vermont   (United States)

^e HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^f Breast Center   (Switzerland)

^g SWISS GROUP FOR CLINICAL CANCER RESEARCH SAKK   (Switzerland)

^h SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

ⁱ CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^j UNIVERSITY OF SYDNEY   (Australia)

^k EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^l ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

more..

Author keywords

Adjuvant! Online; Chemotherapy; Endocrine therapy; Estrogen receptor; International Breast Cancer Study Group; Premenopausal

Indexed keywords

CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR; GOSERELIN; TAMOXIFEN; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; SELECTIVE ESTROGEN RECEPTOR MODULATOR;

ADULT; ARTICLE; AXILLARY LYMPH NODE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMPUTER PREDICTION; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HUMAN; LAPAROSCOPIC SURGERY; LAPAROTOMY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; OVARIECTOMY; PREMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPEATED DRUG DOSE; TREATMENT OUTCOME; ADJUVANT CHEMOTHERAPY; BIOSYNTHESIS; BREAST TUMOR; GENETICS; INTERNET; MIDDLE AGED; RISK FACTOR;

ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR MODULATORS; FEMALE; HUMANS; INTERNET; MIDDLE AGED; PREMENOPAUSE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RISK FACTORS; SOFTWARE; TAMOXIFEN; TREATMENT OUTCOME;

EID: 77955773511     PISSN: 01676806     EISSN: 15737217     Source Type: Journal    
DOI: 10.1007/s10549-010-0794-2     Document Type: Article

References (17)

1. Adjuvant! Inc (2009) Adjuvant! for Breast Cancer (Version 8.0). http://www.adjuvantonline.com. Accessed 9 Jul 2009
2. PM Ravdin LA Siminoff GJ Davis MB Mercer J Hewlett N Gerson HL Parker 2001 Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer J Clin Oncol 19 980 991 1:STN:280: DC%2BD3M3gsFalsg%3D%3D 11181660
3. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 1998 Polychemotherapy for early breast cancer: an overview of the randomised trials Lancet 352 930 952 10.1016/S0140-6736(98)03301-7 (Pubitemid 28427277)
4. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) 2005 Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials Lancet 365 1687 1717 10.1016/S0140-6736(05)66544-0 (Pubitemid 40719106)
5. International Breast Cancer Study Group 2001 Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93 The Breast 10 Suppl 3 130 138
6. B Thürlimann KN Price RD Gelber SB Holmberg D Crivellari M Colleoni,, et al. 2009 Is chemotherapy necessary for premenopausal women with lower-risk node-positive, endocrine responsive breast cancer? 10-year update of International Breast Cancer Study Group Trial 11-93 Breast Cancer Res Treat 113 137 144 10.1007/s10549-008-9912-9 18259856
7. Klijn JGM, Blamey RW, Boccardo F, Tominaga T, Duchateau L, Sylvester R for the Combined Hormone Agents Trialists' Group and the European Organization for Research and Treatment of Cancer (2001) Combined tamoxifen and luteinizing hormone-releasing hormone (LHRH) agonist versus LHRH agonist alone in premenopausal advanced breast cancer: A meta-analysis of four randomized trials. J Clin Oncol 19:343-353
8. B Fisher AM Brown NV Dimitrov R Poisson C Redmond RG Margolese D Bowman N Wolmark DL Wickerham CG Kardinal,, et al. 1990 Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15 J Clin Oncol 8 1483 1496 1:STN:280:DyaK3czmt1Wltg%3D%3D 2202791
9. TM) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711-1717
10. R Jakesz H Hausmaninger E Kubista M Gnant C Menzel T Bauernhofer M Seifert K Haider B Mlineritsch P Steindorfer W Kwasny M Fridrik G Steger V Wette H Samonigg 2002 Randomized adjuvant trial of tamoxifen and goserelin versus cyclophosphamide, methotrexate and fluorouracil: evidence for the superiority of treatment with endocrine blockade in premenopausal patients with hormone-responsive breast cancer-Austrian Breast and Colorectal Cancer Study Group Trial 5 J Clin Oncol 20 4621 4627 10.1200/JCO.2002.09.112 1:CAS:528:DC%2BD38XptlGiu7g%3D 12488405 (Pubitemid 36025277)
11. H Roché P Kerbrat J Bonneterre P Fargeot P Fumoleau P Monnier P Clavère M-J Goudier P Chollet J-P Guastalla D Serin 2006 Complete hormonal blockade versus epirubicin-based chemotherapy in premenopausal, one to three node-positive, and hormone-receptor positive, early breast cancer patients: 7-year follow-up results of French Adjuvant Study Group 06 randomised trial Annals Oncol 17 1221 1227 10.1093/annonc/mdl107 (Pubitemid 44288212)
12. MM Regan O Pagani B Walley R Torrisi EA Perez P Francis,, et al. 2008 Premenopausal endocrine-responsive early breast cancer: who receives chemotherapy? Ann Oncol 19 1231 1241 10.1093/annonc/mdn037 1:STN:280: DC%2BD1cvgvVOlsg%3D%3D 18325918 (Pubitemid 351911951)
13. Breast International Group (2009) MINDACT (Microarray in node negative disease may avoid chemotherapy) trial. http://www.breastinternationalgroup.org/ TransBIG/Mindact.aspx. Accessed 9 Jul 2009
14. National Cancer Institute (2009) US National Institutes of Health The TAILORx breast cancer trial. http://www.cancer.gov/clinicaltrials/digestpage/ TAILORx. Accessed 9 Jul 2009
15. I Olivotto C Bajdik P Ravdin C Speers A Coldman B Norris G Davis S Chia K Gelmon 2005 Population-based validation of the prognostic model ADJUVANT! for early breast cancer J Clin Oncol 23 2716 2725 10.1200/JCO.2005.06.178 15837986 (Pubitemid 46179461)
16. HE Campbell MA Taylor AL Harris AM Gray 2009 An investigation into the performance of the Adjuvant! Online prognostic programme in early breast cancer for a cohort of patients in the United Kingdom Br J Cancer 101 1074 1084 10.1038/sj.bjc.6605283 1:STN:280:DC%2BD1MnlsFeisA%3D%3D 19724274
17. Gnant M, Mlineritsch B, Schippinger W, Luschin-Ebengreuth G, Pöstlberger S, Menzel C,, et al. (2009) Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med 60:679-91 (Erratum in: N Engl J Med 360:2379)